SEARCH

SEARCH BY CITATION

References

  • 1
    Korde N,Kristinsson SY,Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood 2011; 117: 55735581.
  • 2
    Melton LJ,Rajkumar V,Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004; 19: 2530.
  • 3
    Bataille R,Chappard D,Basle M-F. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies. Blood 1996; 87: 47624769.
  • 4
    Woitge HW,Horn E,Keck AV, et al. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001; 47: 686693.
  • 5
    Diamond T,Levy S,Smith A, et al. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J 2001; 31: 272278.
  • 6
    Rajkumar SV,Kyle RA,Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812817.
  • 7
    Dispenzieri A,Kyle RA,Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785789.
  • 8
    Dispenzieri A,Zhang L,Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008; 111: 49084915.
  • 9
    Siegel D,Bilotti E,van Hoeven KH. Serum free light chain analysis for diagnosis, monitoring and prognosis of monoclonal gammopathies. Labmedicine 2009; 40: 363365.
  • 10
    Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009; 15: 56065608.
  • 11
    Aggarwal BB,Kumar A,Aggarwal MS,Shisodia S. Curcumin derived from turmeric curcuma longa: A spice for all seasons. Phytopharm Cancer Chemoprev 2005; 349387.
  • 12
    Bharti AC,Donato N,Singh S,Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-KB and IKBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 10531062.
  • 13
    Bharti AC,Takada Y,Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-KB ligand-induced NF-KB activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 2004; 172: 59405947.
  • 14
    Golombick T,Diamond T,Badmaev V, et al. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance—Its effect on paraproteinemia and the urinary N-telopeptide of type 1 collagen bone turnover marker. Clin Cancer Res 2009; 15: 59175922.
  • 15
    Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749757.
  • 16
    Sharma RA,McLelland HR,Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 18941900.
  • 17
    Sharma RA,Euden SA,Platton SL, et al. Phase 1 clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 68476854.
  • 18
    Lao CD,Ruffin MT,Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 1014.
  • 19
    Hassoun H,Reich L,Kimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132: 155161.
  • 20
    Durie BGM,Harousseau JL,Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 14671473.
  • 21
    Mead GP,Carr-Smith HD,Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348354.
  • 22
    Vadhan-Raj S,Weber DM,Wang M, et al. Curcumin downregulates NF-KB and related genes in patients with multiple myeloma: Results of a phase 1/11 study. Blood 2007; 110: 1177a.
  • 23
    Quesada-Gomez JM,Muschitz C,Gomez-Reino J, et al. The effect of PTH (1–84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: Results of a randomized, open-label clinical trial. Osteoporosis International DOI:10.1007/s00198-010-1460-6.
  • 24
    Aggarwal BB,Sundaram C,Malani N,Ichikawa H. Curcumin: The Indian solid gold. Adv Exp Med Biol 2007; 595: 175.
  • 25
    Shishodia S,Sethi G,Aggarwal BB. Curcumin: Getting back to the roots. Ann NY Acad Sci 2005; 1056: 206217.
  • 26
    von Metzler I,Krebbel H,Kuckelkorn U, et al. Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IkB kinase. J Cancer Res Clin Oncol 2009; 135: 173179.
  • 27
    Folwarczna J,Zych M,Trzeciak HI. Effects of curcumin on the skeletal system in rats. Pharmacol Rep 2010; 62: 900909.